In vitro effect of aspartame in angiogenesis induction

Toxicology in Vitro

Volumn 25, Issue 1, 2011, Pages 286-293

  Alleva, Renata ^a   Borghi, Battista ^a   Santarelli, Lory ^b   Strafella, Elisabetta ^b   Carbonari, Damiano ^b,c   Bracci, Massimo ^b   Tomasetti, Marco ^b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Department of Occupational Hygiene   (Italy)

Author keywords

Angiogenesis; Aspartame; Genotoxicity; IL 6; ROS; VEGF

Indexed keywords

ASPARTAME; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; SYNAPTOPHYSIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; ASSAY; CELL CULTURE; CELL DEATH; CELL VIABILITY; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

ANGIOGENESIS INDUCING AGENTS; ASPARTAME; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; FIBROBLASTS; HUMANS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; NEOVASCULARIZATION, PHYSIOLOGIC; OSMOLAR CONCENTRATION; REACTIVE OXYGEN SPECIES; RECEPTORS, INTERLEUKIN-6; SOLUBILITY; SWEETENING AGENTS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78650494478     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.09.002     Document Type: Article

References (51)

1. Adachi Y., Aoki C., Yoshio-Hoshino N., Takayama K., Curiel D.T., Nishimoto N. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int. J. Cancer 2006, 119:1303-1311.
2. Ara T., Declerck Y.A. Interleukin-6 in bone metastasis and cancer progression. Eur. J. Cancer. 2010, 46:1223-1231.
3. Baghurst K.I., Baghurst P.A., Record S.J. Public perceptions of the role of dietary and other environmental factors in cancer causation or prevention. J. Epidemiol. Community Health 1992, 46:120-126.
4. Bandyopadhyay A., Ghoshal S., Mukherjee A. Genotoxicity testing of low-calorie sweeteners: aspartame, acesulfame-K, and saccharin. Drug. Chem. Toxicol. 2008, 31:447-457.
5. Belpoggi F., Soffritti M., Padovani M., Degli Esposti D., Lauriola M., Minardi F. Results of long-term carcinogenicity bioassay on Sprague-Dawley rats exposed to aspartame administered in feed. Ann. N. Y. Acad. Sci. 2006, 1076:559-577.
6. Bosetti C., Gallus S., Salamini R., Montella M., Franceschi S., Negri E., La Vecchia C. Artificial sweeteners and the risk of gastric, pancreatic, and endometrial cancers in Italy. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2235-2238.
7. Brennan S.F., Cantwell M.M., Cardwell C.R., Velentzis L.S., Woodside J.V. Dietary patterns and breast cancer risk: a systematic review and meta-analysis. Am. J. Clin. Nutr. 2010, 91:1294-1302.
8. Butchko H.H., Kotsonis F.N. Acceptable daily intake vs actual intake: the aspartame example. J. Am. Coll. Nutr. 1991, 10:258-266.
9. Byers T., Nestle M., McTiernan A., Doyle C., Currie-Williams A., Gansler T., Thun M. American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2002, 52:92-119.
10. Demark-Wahnefried W., Morey M.C., Sloane R., Snyder D.C., Cohen H.J. Promoting healthy lifestyles in older cancer survivors to improve health and preserve function. J. Am. Geriatr. Soc. 2009, 57:S262-264.
11. Desai B.S., Schneider J.A., Li J.L., Carvey P.M., Hendey B. Evidence of angiogenic vessels in Alzheimer's disease. J. Neural. Transm. 2009, 116:587-597.
12. FDA (food and drug administration) Aspartame commissioner's final decision. Fed. Reg. 1981, 46:38285-38308.
13. FDA (food and drug administration) Food additive permitted for direct addition to food for human consumption: aspartame. Fed. Reg. 1983, 48:31376-31382.
14. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 1986, 46:467-473.
15. Folkman J. Growth control in capillary endothelium. Dev. Biol. 1986, 3:101-110. (N Y 1985).
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
17. Hagiwara A., Fukushima S., Kitaori M., Shibata M., Ito N. Effects of three sweeteners on rat urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Gann 1984, 75:763-768.
18. Horton E.S. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring) 2009, 1:S43-48.
19. Husøy T., Mangschou B., Fotland T.Ø., Kolset S.O., Nøtvik Jakobsen H., Tømmerberg I., Bergsten C., Alexander J., Frost Andersen L. Reducing added sugar intake in Norway by replacing sugar sweetened beverages with beverages containing intense sweeteners - a risk benefit assessment. Food. Chem. Toxicol. 2008, 46:3099-3105.
20. Ishii H. Incidence of brain tumors in rats fed aspartame. Toxicol. Lett. 1981, 7:433-437.
21. Janiszewski P.M., Ross R. The utility of physical activity in the management of global cardiometabolic risk. Obesity (Silver Spring) 2009, 17:S3-S14.
22. Jeffrey A.M., Williams G.M. Lack of DNA-damaging activity of five non-nutritive sweeteners in the rat hepatocyte/DNA repair assay. Food. Chem. Toxicol. 2000, 38:335-338.
23. Jude E.B., Eleftheriadou I., Tentolouris N. Peripheral arterial disease in diabetes - a review. Diabet. Med. 2010, 27:4-14.
24. Kitadai Y. Angiogenesis and lymphangiogenesis of gastric cancer. J. Oncol. 2010, 468725.
25. Kou B., Li Y., Zhang L., Zhu G., Wang X., Li Y., Xia J., Shi Y. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp. Mol. Pathol. 2004, 76:129-137.
26. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 2001, 61:253-270.
27. Lino C.M., Costa I.M., Pena A., Ferriera R., Cardoso S.M. Estimated intake of the sweeteners, acesulfame-K and aspartame, from soft drinks, soft drinks based on mineral waters and nectars for a group of Portuguese teenage students. Food. Addit. Contam. 2008, 20:1-6.
28. Maffei R., Martinelli S., Castelli I., Santachiara R., Zucchini P., Fontana M., Fiorcari S., Bonacorsi G., Ilariucci F., Torelli G., Marasca R. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk. Res. 2010, 34:312-321.
29. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
30. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005, 65:10794-10800.
31. Patel A.C., Nunez N.P., Perkins S.N., Barrett J.C., Hursting S.D. Effects of energy balance on cancer in genetically altered mice. J. Nutr. 2004, 134:3394S-3398S.
32. Petruzzelli G.J. The biology of tumor invasion, angiogenesis and lymph node metastasis. ORL J. Otorhinolaryngol. Relat. Spec. 2000, 62:178-185.
33. Ranney R.E., Oppermann J.A. A review of the metabolism of the aspartyl moiety of aspartame in experimental animals and man. J. Environ. Pathol. Toxicol. 1979, 2:979-985.
34. Rencüzoĝullari E., Tüylü B.A., Topaktaş M., Ila H.B., Kayraldiz A., Arslan M., Diler S.B. Genotoxicity of aspartame. Drug. Chem. Toxicol. 2004, 27:257-268.
35. Soffritti M., Belpoggi F., Degli Esposti D., Lambertini L., Ribaldi E., Rigano A. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats. Environ. Health. Perspect. 2006, 114:379-385.
36. Soffritti M., Belpoggi F., Ribaldi E., Degli Esposti D., Lauriola M. Life-span exposure to low doses of aspartame beginning during prenatal life increases cancer effects in rats. Environ. Health. Perspect. 2007, 115:1293-1297.
37. Stone J.R., Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002, 9:231-238.
38. Szekanecz Z., Besenyei T., Szentpétery A., Koch A.E. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol. 2010, 22:299-306.
39. Takahashi H., Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. 2005, 109:227-241.
40. Tephly T.R. Comments on the purported generation of formaldehyde and adduct formation from the sweetener aspartame. Life Sci. 1999, 65:157-160.
41. Tosetti F., Noonan D.M., Albini A. Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals. Int. J. Cancer 2009, 125:1997-2003.
42. Trefz F., de Sonneville L., Matthis P., Benninger C., Lanz-Englert B., Bickel H. Neuropsychological and biochemical investigations in heterozygotes for phenylketonuria during ingestion of high dose aspartame (a sweetener containing phenylalanine). Hum. Genet. 1994, 93:369-374.
43. Trocho C., Pardo R., Rafecas I., Virgili J., Remesar X., Fernández-López J.A., Alemany M. Formaldehyde derived from dietary aspartame binds to tissue components in vivo. Life Sci. 1998, 63:337-349.
44. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc. Res. 2006, 71:226-235.
45. Vedula S.S., Krzystolikm M.G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neurovascular age-related macular degeneration. Cochrane Database Syst. Rev. 2008, 16:CD005139.
46. Waltenberger J. VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem. Soc. Trans. 2009, 37:1167-1170.
47. Weihrauch M.R., Diehl V. Artificial sweeteners-do they bear a carcinogenic risk?. Ann. Oncology 2004, 15:1460-1465.
48. Whitehouse C.R., Boullata J., McCauley L.A. The potential toxicity of artificial sweeteners. A.A.O.H.N. J. 2008, 56:251-259.
49. Wu F.T.H., Stefanini M.O., Gabhann F.M., Kontos C.D., Annex B.H., Popel A.S. A systems biology perspective on sVEGF1: its biological function, pathogenic role and therapeutic use. J. Cell. Mol. Med. 2010, 14:528-552.
50. Yi-Nong N., Shu-Jie X. Stroma-epithelium crosstalk in prostate cancer. Asian. J. Andrology 2009, 11:28-35.
51. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 2003, 31:1171-1177.